#USA #Cambridge #Leap Therapeutics #Sirexatamab #Cypherpunk Technologies

Leap Therapeutics Unveils Groundbreaking Results from the DeFianCe Study

Leap Therapeutics, Inc., a biotechnology branch of Cypherpunk Technologies Inc. (Nasdaq: CYPH), has made headlines with the recent publication of their analyzed results from the DeFianCe study. This Phase 2 clinical trial evaluated the effects of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy for treating advanced colorectal cancer. The results, featured in Clinical Cancer Research, add an exciting perspective to ongoing cancer therapies.

Understanding the Study and Its Results

The publication titled, "Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma the Phase II DeFianCe Trial," provides a comprehensive overview of the efficacy, safety, and biomarker analyses derived from this randomized study. The pivotal message from this report is the significant correlation between baseline plasma DKK1 levels and patient outcomes.

In patients with high DKK1 levels in advanced metastatic colorectal cancer (mCRC), the addition of sirexatamab demonstrated enhanced response rates, prolonging progression-free survival (PFS) and overall survival (OS). The study's findings indicate that as the baseline plasma DKK1 increases, the effectiveness of sirexatamab elevates, meeting a vital need in treatment for mCRC patients—a unique population facing aggressive disease and limited therapeutic options.

Key Findings of the DeFianCe Study

The DeFianCe research comprised two parts, with Part B involving 188 patients who were either treated with sirexatamab combined with chemotherapy and bevacizumab or given chemotherapy and bevacizumab alone.
Highlighted findings include:

• - Objective Response Rate (ORR): In patients with DKK1 levels above the median, the ORR for those on the sirexatamab arm reached 38.0%, compared to 23.7% in the control group.
• - Median PFS: Patients treated with sirexatamab showed a median PFS of 9.0 months against the control group’s 7.1 months.
• - Median OS: Notably, median OS achieved statistical significance at 0.42 for patients on sirexatamab, indicating a lasting benefit with the treatment.

For patients within the upper quartile of baseline DKK1, results were even more impressive:

• - ORR surged to 44.0% in the sirexatamab arm versus 15.8% for controls.
• - Median PFS and OS further validated the strong potential of sirexatamab in improving patient outcomes.

The Importance of DKK1 as a Biomarker

The study underscores DKK1 as a crucial biomarker that provides insight into patient prognosis and personalized treatment options. The relationship between high baseline plasma DKK1 and chemotherapy outcomes emphasizes a dire need for identifying patients who can benefit the most from advanced therapies. According to Zev Wainberg, MD, a key study investigator, identifying those with high DKK1 levels will lead to improved treatment strategies tailored to these patients’ needs.

Markus Moehler, MD, PhD, also emphasized how vital it is to develop innovative biomarkers in tackling colorectal cancer, particularly regarding patient selection for further therapies.

Safety Profile and Next Steps

The safety assessments indicated that combining sirexatamab with standard chemotherapy was generally well-tolerated, with comparable rates of treatment-emergent adverse events across both study arms. With the results showing promise, Leap Therapeutics is focusing on advancing the sirexatamab therapeutic process.

The implications of this study advocate for moving towards a biomarker-selected Phase 3 trial, which may confirm the significant benefits of sirexatamab, ultimately aiming to enhance overall treatment pathways for colorectal cancer patients.

Conclusion

As oncology continues to evolve, the publication of the DeFianCe study results marks an important milestone for Leap Therapeutics and the advancement of targeted therapies in colorectal cancer. With DKK1 standing as a reliable biomarker for understanding patient outcomes, the future for patients suffering from this disease may potentially look brighter.